Transcend Capital Advisors LLC Grows Position in Eli Lilly and Company (NYSE:LLY)

Transcend Capital Advisors LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 2.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,781 shares of the company’s stock after acquiring an additional 336 shares during the period. Eli Lilly and Company comprises about 0.8% of Transcend Capital Advisors LLC’s investment portfolio, making the stock its 26th biggest position. Transcend Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $8,616,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $26,000. Thompson Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the third quarter valued at about $27,000. Legacy Financial Group LLC purchased a new position in shares of Eli Lilly and Company in the third quarter valued at about $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company in the third quarter valued at about $36,000. Finally, Family CFO Inc purchased a new position in shares of Eli Lilly and Company in the third quarter valued at about $40,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 1.2 %

Shares of NYSE LLY traded up $8.64 during midday trading on Friday, hitting $733.51. The company’s stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The business’s 50 day moving average is $761.79 and its two-hundred day moving average is $666.06. Eli Lilly and Company has a 12-month low of $380.77 and a 12-month high of $800.78. The firm has a market cap of $696.95 billion, a P/E ratio of 126.47, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the business posted $2.09 earnings per share. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. Morgan Stanley boosted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Barclays boosted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research report on Wednesday, February 21st. Finally, JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.